Overall Score

Revenue Market Opportunity

Ocular Therapeutix operates in a large ophthalmology market with room for adoption if its sustained-release eye therapies continue to gain traction.

Revenue per share remains low at 0.2314, indicating the business is still early in monetization relative to its market value.

Profitability Cash Flow

Gross margin is strong at 87.1%, but operating margin (-6.0%) and net margin (-5.8%) remain deeply negative.

Free cash flow is negative, with free cash flow yield at -11.5% and operating cash flow yield at -7.2%, showing the company is still burning cash.

Balance Sheet Capital Efficiency

Liquidity is very strong, with a current ratio of 13.1 and cash ratio of 12.2, giving the company substantial near-term flexibility.

Leverage is modest, but returns on capital remain negative, with ROIC at -50.2% and ROE at -59.9%, indicating poor capital efficiency.

Valuation Shareholder Returns

The stock remains expensive on sales at 42.8x EV/sales, which leaves little room for disappointment.

There is no dividend support, and valuation is not yet backed by positive earnings or free cash flow.

Execution Durability

High gross margins suggest a potentially durable product profile if commercialization scales successfully.

However, the company still faces execution risk because profitability, cash generation, and capital returns are all negative.